HCW Biologics Q4 revenue drops sharply on license suspension

Overview

• U.S. biopharmaceutical firm's Q4 2025 revenue declined sharply yr/yr amid license suspension

• Basic EPS for Q4 was -1.02, reflecting continued net losses

• Company received $3.5 mln upfront license fee for HCW11-006 and launched two commercial-ready reagents

Outlook

• Company says substantial doubt exists about ability to continue as going concern without additional funding

• Company expects preliminary human data from HCW9302 Phase 1 trial in first half of 2026

• Company plans to appeal Nasdaq notice on minimum bid price non-compliance

Result Drivers

• LICENSE SUSPENSION - Revenue decline attributed to one-year suspension of Wugen license agreement, allowing co to market HCW9206 and HCW9201 as reagents

• R&D SPENDING - Q4 R&D expenses increased 27% yr/yr, driven by ongoing clinical development activities

• REAGENT LAUNCH - Co launched two proprietary fusion protein molecules as commercial-ready reagents to support cell-based immunotherapeutics production

Company press release: ID:nGNX1bkw6c

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "buy"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for HCW Biologics Inc is $2.00, about 454.2% above its March 30 closing price of $0.36

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.